Ublituximab

ATC Code L04AG14

Ublituximab

Definition

A chimeric recombinant IgG1 monoclonal antibody directed against human CD20 with potential antineoplastic activity. Ublituximab specifically binds to the B cell-specific cell surface antigen CD20, thereby potentially inducing a B cell-directed complement dependent cytotoxicity (CDC) and antibody-dependent cell-mediated cytotoxicity (ADCC) against CD20-expressing B cells, leading to B cell apoptosis. CD20 is a non-glycosylated cell surface phosphoprotein that is exclusively expressed on B cells during most stages of B cell development and is often overexpressed in B-cell malignancies. Ublituximab has a specific glycosylation profile, with a low fucose content, that may enhance its ADCC response against malignant B cells.

Also known as Briumvi, LFB R603, LFB-R603, LFBR603, TG 1101, TG 20, TG-1101, TG-20, TG1101, TG20, TGTX 1101, TGTX-1101, TGTX1101, UBLITUXIMAB, Ublituximab-xiiy — per NCIT

Also identified as

Indications

Disease Relation Source
Chronic progressive multiple sclerosis may treat MEDRT · Public domain (U.S. Government work)
Demyelinating disease may treat MEDRT · Public domain (U.S. Government work)
Relapsing-remitting multiple sclerosis may treat MEDRT · Public domain (U.S. Government work)

Organ Effects

Organ Side effect / interaction Source
Central nervous system may treat a disease of this organ DERIVED · CC BY 4.0
Nervous system may treat a disease of this organ DERIVED · CC BY 4.0

2 entries above are marked DERIVED: Atlas Médico inferred them by combining two sourced claims, and no source asserts these links directly. Treat them as a navigation aid, not as a clinical statement.